|
[1]
|
Allam, J.P., Bieber, T. and Novak, N. (2005) Recent Highlights in the Pathophysiology of Atopic Eczema. International Archives of Allergy and Immunology, 136, 191-197. [Google Scholar] [CrossRef] [PubMed]
|
|
[2]
|
Guttman-Yassky, E., Krueger, J.G. and Lebwohl, M.G. (2017) Systemic Immune Mechanisms in Atopic Dermatitis and Psoriasis with Implications for Treatment. Experimental Dermatology, 27, 409-417. [Google Scholar] [CrossRef] [PubMed]
|
|
[3]
|
Mansouri, Y. and Guttman-Yassky, E. (2015) Immune Pathways in Atopic Dermatitis, and Definition of Biomarkers through Broad and Targeted Therapeutics. Journal of Clinical Medicine, 4, 858-873. [Google Scholar] [CrossRef] [PubMed]
|
|
[4]
|
Arima, K., Gupta, S., Gadkari, A., et al. (2018) Burden of Atopic Der-matitis in Japanese Adults: Analysis of Data from the 2013 National Health and Wellness Survey. The Journal of Dermatology, 45, 390-396. [Google Scholar] [CrossRef] [PubMed]
|
|
[5]
|
Igarashi, A., Fujita, H., Arima, K., Inoue, et al. (2019) Health-Care Resource Use and Current Treatment of Adult Atopic Dermatitis Patients in Japan: A Retrospective Claims Database Analysis. The Journal of Dermatology, 46, 652-661. [Google Scholar] [CrossRef] [PubMed]
|
|
[6]
|
Jung, H.J., Bae, J.Y., Kim, J.E., et al. (2018) Survey of Disease Awareness, Treatment Behavior and Treatment Satisfaction in Pa-tients with Atopic Dermatitis in Korea: A Multicenter Study. The Journal of Dermatology, 45, 1172-1180. [Google Scholar] [CrossRef] [PubMed]
|
|
[7]
|
Komura, Y., Kogure, T., Kawahara, K., et al. (2018) Economic Assessment of Actual Prescription of Drugs for Treatment of Atopic Dermatitis: Differences between Dermatology and Pediatrics in Large-Scale Receipt Data. The Journal of Dermatology, 45, 165-174. [Google Scholar] [CrossRef] [PubMed]
|
|
[8]
|
Takeuchi, S., Oba, J., Esaki, H., et al. (2018) Non-Corticosteroid Adherence and Itch Severity Influence Perception of Itch in Atopic Dermatitis. The Journal of Dermatology, 45, 158-164. [Google Scholar] [CrossRef] [PubMed]
|
|
[9]
|
Williams, H., Stewart, A., von Mutius, E., et al. (2008) Is Eczema Really on the Increase Worldwide? Journal of Allergy and Clinical Immunology, 121, 947-954. [Google Scholar] [CrossRef] [PubMed]
|
|
[10]
|
Van den Bogaard, E.H., Bergboer, J.G., Vonk-Bergers, M., et al. (2013) Coal Tar Induces AHR-Dependent Skin Barrier Repair in Atopic Dermatitis. Journal of Clinical Investigation, 123, 917-927. [Google Scholar] [CrossRef]
|
|
[11]
|
Geng, S., Mezentsev, A., Kalachikov, S., et al. (2006) Tar-geted Ablation of Arnt in Mouse Epidermis Results in Profound Defects in Desquamation and Epidermal Barrier Func-tion. Journal of Cell Science, 119, 4901-4912. [Google Scholar] [CrossRef] [PubMed]
|
|
[12]
|
王建琴. 中国特应性皮炎诊疗指南(2020版)解读[J]. 皮肤性病诊疗学杂志, 2020, 27(5): 359-361.
|
|
[13]
|
Czarnowicki, T., Gonzalez, J., Bonifacio, K.M., et al. (2016) Diverse Activation and Differentiation of Multiple B-Cell Subsets in Patients with Atopic Dermatitis but Not in Patients with Psoriasis. Journal of Allergy and Clinical Immunology, 137, 118-129.e115. [Google Scholar] [CrossRef] [PubMed]
|
|
[14]
|
Hamada, M., Furusyo, N., Urabe, K., et al. (2005) Prevalence of Atopic Dermatitis and Serum IgE Values in Nursery School Children in Ishigaki Island, Okinawa, Japan. The Journal of Dermatology, 32, 248-255. [Google Scholar] [CrossRef] [PubMed]
|
|
[15]
|
Gittler, J.K., Shemer, A., Suárez-Fariñas, M., et al. (2012) Progressive Activation of T(H)2/T(H)22 Cytokines and Selective Epidermal Proteins Characterizes Acute and Chronic Atopic Dermatitis. Journal of Allergy and Clinical Immunology, 130, 1344-1354. [Google Scholar] [CrossRef] [PubMed]
|
|
[16]
|
Koga, C., Kabashima, K., Shiraishi, N., et al. (2008) Possible Pathogenic Role of Th17 Cells for Atopic Dermatitis. Journal of Investigative Dermatology, 128, 2625-2630. [Google Scholar] [CrossRef] [PubMed]
|
|
[17]
|
Furue, M., Iida, K., Imaji, M., et al. (2018) Microbiome Analysis of Forehead Skin in Patients with Atopic Dermatitis and Healthy Subjects: Implication of Staphylococcus and Corynebacterium. The Journal of Dermatology, 45, 877. [Google Scholar] [CrossRef] [PubMed]
|
|
[18]
|
Iwamoto, K., Moriwaki, M., Miyake, R., et al. (2019) Staphylo-coccus aureus in Atopic Dermatitis: Strain-Specific Cell Wall Proteins and Skin Immunity. Allergology International, 68, 309-315. [Google Scholar] [CrossRef] [PubMed]
|
|
[19]
|
Bissonnette, R., Poulin, Y., Zhou, Y., et al. (2012) Efficacy and Safety of Topical WBI-1001 in Patients with Mild to Severe Atopic Dermatitis: Results from a 12-Week, Multicentre, Randomized, Placebo-Controlled Double-Blind Trial. Br. The Journal of Dermatology, 166, 853-860. [Google Scholar] [CrossRef] [PubMed]
|
|
[20]
|
Keam, S.J. (2022) Tapinar of Cream 1%: First Approval. Drugs, 82, 1221-1228. [Google Scholar] [CrossRef] [PubMed]
|
|
[21]
|
Li, J., Chen, G., Wu, H., et al. (1995) Identification of Two Pigments and a Hydroxystilbene Antibiotic from Photorhabdus luminescens. Applied and Environmental Microbiology, 61, 4329-4333. [Google Scholar] [CrossRef] [PubMed]
|
|
[22]
|
Richardson, W.H., Schmidt, T.M. and Nealson, K.H. (1988) Identification of an Anthraqui-None Pigment and a Hydroxystilbene Antibiotic from Xenorhabdus luminescens. Applied and Environmental Microbiology, 54, 1602-1605. [Google Scholar] [CrossRef] [PubMed]
|
|
[23]
|
Bissonnette, R., Chen, G., Bolduc, C., et al. (2010) Efficacy and Safety of Topical WBI-1001 in the Treatment of Atopic Dermatitis: Results from a Phase 2A, Randomized, Placebo-Controlled Clinical Trial. Archives of Dermatology, 146, 446-449. [Google Scholar] [CrossRef] [PubMed]
|
|
[24]
|
Smith, S.H., Jayawickreme, C., Rickard, D.J., et al. (2017) Tapinarof Is a Natural AhR Agonist that Resolves Skin Inflammation in Mice and Humans. Journal of Investigative Dermatology, 137, 2110-2119. [Google Scholar] [CrossRef] [PubMed]
|
|
[25]
|
Tsuji, G., Takahara, M., Uchi, H., et al. (2012) Identification of Ketoconazole as an AhR-Nrf2 Activator in Cultured Human Keratinocytes: The Basis of Its Anti-Inflammatory Effect. Journal of Investigative Dermatology, 132, 59-68. [Google Scholar] [CrossRef] [PubMed]
|
|
[26]
|
Hwang, J., Newton, E.M., Hsiao, J., et al. (2022) Aryl Hydrocarbon Receptor/Nuclear Factor E2-Related Factor 2 (AHR/NRF2) Signalling: A Novel Therapeutic Target for Atopic Dermatitis. Experimental Dermatology, 31, 485-497. [Google Scholar] [CrossRef] [PubMed]
|
|
[27]
|
Mimura, J. and Fujii-Kuriyama, Y. (2003) Functional Role of AhR in the Expression of Toxic Effects by TCDD. Biochimica et Biophysica Acta, 1619, 263-268. [Google Scholar] [CrossRef]
|
|
[28]
|
Hayes, J.D. and McMahon, M. (2001) Molecular Basis for the Contribution of the Antioxidant Responsive Element to Cancer Chemoprevention. Cancer Letters, 174, 103-113. [Google Scholar] [CrossRef]
|
|
[29]
|
Miao, W., Hu, L., Scrivens, P.J., et al. (2005) Transcriptional Regulation of NF-E2 p45-Related Factor (NRF2) Expression by the Aryl Hydrocarbon Receptor-Xenobiotic Response Element Signaling Pathway: Direct Cross-Talk between Phase I and II Drug-Metabolizing Enzymes. Journal of Biological Chemistry, 280, 20340-20348. [Google Scholar] [CrossRef]
|
|
[30]
|
Esser, C. and Rannug, A. (2015) The Aryl Hydrocarbon Receptor in Barrier Organ Physiology, Immunology, and Toxicology. Pharmacological Reviews, 67, 259-279. [Google Scholar] [CrossRef] [PubMed]
|
|
[31]
|
Esser, C. (2016) The Aryl Hydrocarbon Receptor in Immunity: Tools and Potential. Methods in Molecular Biology, 1371, 239-257. [Google Scholar] [CrossRef] [PubMed]
|
|
[32]
|
Stockinger, B., Di Meglio, P., Gialitakis, M., et al. (2014) The Aryl Hydrocarbon Receptor: Multitasking in the Immune System. Annual Review of Immunology, 32, 403-432. [Google Scholar] [CrossRef] [PubMed]
|
|
[33]
|
Mischke, D., Korge, B.P., Marenholz, I., et al. (1996) Genes Encoding Structural Proteins of Epidermal Cornification and S100 Calcium-Binding Proteins form a Gene Complex (“Epidermal Differentiation Complex”) on Human Chromosome 1q21. Journal of Investigative Dermatology, 106, 989-992. [Google Scholar] [CrossRef] [PubMed]
|
|
[34]
|
Sutter, C.H., Bodreddigari, S., Campion, C., et al. (2011) 2,3,7,8-Tetrachlorodibenzo-p-dioxin Increases the Expression of Genes in the Human Epidermal Differentiation Complex and Accelerates Epidermal Barrier Formation. Toxicological Sciences, 124, 128-137. [Google Scholar] [CrossRef] [PubMed]
|
|
[35]
|
Stemmler, S., Nothnagel, M., Parwez, Q., et al. (2009) Variation in Genes of the Epidermal Differentiation Complex in German Atopic Dermatitis Patients. International Journal of Immunogenetics, 36, 217-222. [Google Scholar] [CrossRef]
|
|
[36]
|
Furue, M. (2020) Regulation of Filaggrin, Loricrin, and Involucrin by IL-4, IL-13, IL-17A, IL-22, AHR, and NRF2: Pathogenic Implications in Atopic Dermatitis. International Journal of Molecular Sciences, 21, 5382. [Google Scholar] [CrossRef] [PubMed]
|
|
[37]
|
Nomura, T., Sandilands, A., Akiyama, M., et al. (2007) Unique Muta-tions in the Filaggrin Gene in Japanese Patients with Ichthyosis Vulgaris and Atopic Dermatitis. Journal of Allergy and Clinical Immunology, 119, 434-440. [Google Scholar] [CrossRef] [PubMed]
|
|
[38]
|
Palmer, C.N.A., Irvine, A.D., Terron-Kwiatkowski, A., et al. (2006) Common Loss-of-Function Variants of the Epidermal Barrier Protein Filaggrin Are a Major Predisposing Factor for Atopic Dermatitis. Nature Genetics, 38, 441-446. [Google Scholar] [CrossRef] [PubMed]
|
|
[39]
|
Steinert, P.M. and Marekov, L.N. (1995) The Proteins Elafin, Filaggrin, Keratin Intermediate Filaments, Loricrin, and Small Proline-Rich Proteins 1 and 2 Are Isodipeptide Cross-Linked Components of the Human Epidermal Cornified Cell Envelope. Journal of Biological Chemistry, 270, 17702-17711. [Google Scholar] [CrossRef] [PubMed]
|
|
[40]
|
Hudson, T.J. (2006) Skin Barrier Function and Allergic Risk. Na-ture Genetics, 38, 399-400. [Google Scholar] [CrossRef] [PubMed]
|
|
[41]
|
Candi, E., Melino, G., Mei, G., et al. (1995) Biochemical, Structural, and Transglutaminase Substrate Properties of Human Loricrin, the Major Epidermal Cornified Cell Envelope Protein. Journal of Biological Chemistry, 270, 26382- 26390. [Google Scholar] [CrossRef] [PubMed]
|
|
[42]
|
Robinson, N.A., Lapic, S., Welter, J.F., et al. (1997) S100A11, S100A10, Annexin I, Desmosomal Proteins, Small Proline-Rich Proteins, Plasminogen Activator Inhibitor-2, and Involucrin Are Components of the Cornified Envelope of Cultured Human Epidermal Keratinocytes. Journal of Biological Chemistry, 272, 12035-12046. [Google Scholar] [CrossRef] [PubMed]
|
|
[43]
|
Yu, J., Luo, Y., Zhu, Z., et al. (2019) A Tryptophan Metabolite of the Skin Microbiota Attenuates Inflammation in Patients with Atopic Dermatitis through the Aryl Hydrocarbon Receptor. Journal of Allergy and Clinical Immunology, 143, 2108-2119.e2112. [Google Scholar] [CrossRef] [PubMed]
|
|
[44]
|
Buommino, E., Baroni, A., Papulino, C., et al. (2018) Malassezia Pachydermatis Upregulates AhR Related CYP1A1 Gene and Epidermal Barrier Markers in Human Keratinocytes. Medical Mycology, 56, 987-993. [Google Scholar] [CrossRef] [PubMed]
|
|
[45]
|
Furue, M. (2020) Regulation of Skin Barrier Function via Competition between AHR Axis versus IL-13/IL-4-JAK- STAT6/STAT3 Axis: Pathogenic and Therapeutic Implications in Atopic Dermatitis. Journal of Clinical Medicine, 9, 3741. [Google Scholar] [CrossRef] [PubMed]
|
|
[46]
|
Kim, B.E., Leung, D.Y., Boguniewicz, M., et al. (2008) Loricrin and Involucrin Expression Is Down-Regulated by Th2 Cytokines through STAT-6. Clinical Immunology (Orlando, Fla), 126, 332-337. [Google Scholar] [CrossRef] [PubMed]
|
|
[47]
|
Bao, L., Mohan, G.C., Alexander, J.B., et al. (2017) A Molecular Mechanism for IL-4 Suppression of Loricrin Transcription in Epidermal Keratinocytes: Implication for Atopic Dermatitis Pathogenesis. Innate Immunity, 23, 641-647. [Google Scholar] [CrossRef] [PubMed]
|
|
[48]
|
Howell, M.D., Kim, B.E., Gao, P., et al. (2007) Cytokine Mod-ulation of Atopic Dermatitis Filaggrin Skin Expression. Journal of Allergy and Clinical Immunology, 120, 150-155. [Google Scholar] [CrossRef] [PubMed]
|
|
[49]
|
Amano, W., Nakajima, S., Kunugi, H., et al. (2015) The Janus Kinase Inhibitor JTE-052 Improves Skin Barrier Function through Suppressing Signal Transducer and Activator of Transcription 3 Signaling. Journal of Allergy and Clinical Immunology, 136, 667-677.e667. [Google Scholar] [CrossRef] [PubMed]
|
|
[50]
|
Bao, L., Shi, V.Y. and Chan, L.S. (2012) IL-4 Regulates Chemo-kine CCL26 in Keratinocytes through the Jak 1,2/Stat6 Signal Transduction Pathway: Implication for Atopic Dermatitis. Molecular Immunology, 50, 91-97. [Google Scholar] [CrossRef] [PubMed]
|
|
[51]
|
Bao, L., Shi, V.Y. and Chan, L.S. (2013) IL-4 Up-Regulates Epidermal Chemotactic, Angiogenic, and Pro-Inflam- matory Genes and Down-Regulates Antimicrobial Genes in Vivo and in Vitro: Relevant in the Pathogenesis of Atopic Dermatitis. Cytokine, 61, 419-425. [Google Scholar] [CrossRef] [PubMed]
|
|
[52]
|
Tsuji, G., Hashimoto-Hachiya, A., Kiyomatsu-Oda, M., et al. (2017) Aryl Hydrocarbon Receptor Activation Restores Filaggrin Expression via OVOL1 in Atopic Dermatitis. Cell Death & Disease, 8, e2931. [Google Scholar] [CrossRef] [PubMed]
|
|
[53]
|
Takei, K., Mitoma, C., Hashimoto-Hachiya, A., et al. (2015) Antioxi-dant Soybean Tar Glyteer Rescues T-Helper-Media- ted Downregulation of Filaggrin Expression via Aryl Hydrocarbon Receptor. The Journal of Dermatology, 42, 171-180. [Google Scholar] [CrossRef] [PubMed]
|
|
[54]
|
Miake, S., Tsuji, G., Takemura, M., et al. (2019) IL-4 Augments IL-31/IL-31 Receptor Alpha Interaction Leading to Enhanced Ccl17 and Ccl22 Production in Dendritic Cells: Implica-tions for Atopic Dermatitis. International Journal of Molecular Sciences, 20, 60. [Google Scholar] [CrossRef] [PubMed]
|
|
[55]
|
Veldhoe, M., Hirota, K., Westendorf, A.M., et al. (2008) The Aryl Hydrocarbon Receptor Links TH17-Cell-Mediated Autoimmunity to Environmental Toxins. Nature, 453, 106-109. [Google Scholar] [CrossRef] [PubMed]
|
|
[56]
|
Koch, S., Stroisch, T.J., Vorac, J., et al. (2017) AhR Mediates an Anti-inflammatory Feedback Mechanism in Human Langerhans Cells Involving FcεRI and IDO. Allergy, 72, 1686-1693. [Google Scholar] [CrossRef] [PubMed]
|
|
[57]
|
Yoo, O.K., Choi, W.J. and Keum, Y.S. (2020) Cardamonin Inhibits Oxazolone-Induced Atopic Dermatitis by the Induction of NRF2 and the Inhibition of Th2 Cytokine Production. Anti-oxidants (Basel Switzerland), 9, 834. [Google Scholar] [CrossRef] [PubMed]
|
|
[58]
|
Hendricks, A.J., Eichenfield, L.F. and Shi, V.Y. (2020) The Impact of Airborne Pollution on Atopic Dermatitis: A Literature Review. British Journal of Dermatology, 183, 16-23. [Google Scholar] [CrossRef] [PubMed]
|
|
[59]
|
Peppers, J., Paller, A.S., Maeda-Chubachi, T., et al. (2019) A Phase 2, Randomized Dose-Finding Study of Tapinarof (GSK2894512 Cream) for the Treatment of Atopic Dermatitis. Journal of the American Academy of Dermatology, 80, 89-98.e3. [Google Scholar] [CrossRef] [PubMed]
|
|
[60]
|
Paller, A.S., Stein Gold, L., Soung, J., et al. (2021) Efficacy and Patient-Reported Outcomes from a Phase 2b, Randomized Clinical Trial of Tapinarof Cream for the Treatment of Adolescents and Adults with Atopic Dermatitis. Journal of the American Academy of Dermatology, 84, 632-638. [Google Scholar] [CrossRef] [PubMed]
|
|
[61]
|
Bissonnette, R., Vasist, L.S., Bullman, J.N., et al. (2018) Systemic Pharmacokinetics, Safety, and Preliminary Efficacy of Topical AhR Agonist Tapinarof: Results of a Phase 1 Study. Clinical Pharmacology in Drug Development, 7, 524-531. [Google Scholar] [CrossRef] [PubMed]
|